Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate-Reference-Cited by-同舟云学术

Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate

Published:2020-05 Issue:5 Volume:141 Page:397-404
ISSN:0001-6314
Container-title:Acta Neurologica Scandinavica
language:en
Short-container-title:Acta Neurol Scand

Author:

Rogin Joanne¹^ORCID,Resnick Trevor²,Strom Laura³,Ben‐Menachem Elinor⁴,Kochen Silvia⁵,Blum David⁶,Gama Helena⁷,Soares‐da‐Silva Patrício⁷⁸,Li Yan⁶,Grinnell Todd⁶

Affiliation:

1. Midwest Center for Seizure Disorders Minneapolis Clinic of Neurology Golden Valley MN USA

2. Department of Neurology Nicklaus Children’s Hospital Florida International University Miami FL USA

3. Department of Neurology University of Colorado Denver Health Sciences Aurora CO USA

4. Sahlgrenska Academy Institute of Neuroscience and Physiology Goteborg Sweden

5. Neurosciences and Complex Systems Unit (ENyS), Epilepsy Section, CONICET Hospital El Cruce “N. Kirchner” University National A. Jauretche (UNAJ) University Buenos Aires Buenos Aires Argentina

6. Sunovion Pharmaceuticals Inc. Marlborough MA USA

7. BIAL ‐ Portela & C^a, S.A. S. Mamede do Coronado Portugal

8. MedInUP ‐ Center for Drug Discovery and Innovative Medicines University of Porto Porto Portugal

Funder

Fundação Bial

Eisai

UCB

George Washington University

Life Technologies Corporation

Ministerio de Ciencia y Tecnología

Sunovion

Publisher

Wiley

Subject

Neurology (clinical),Neurology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ane.13218

Reference22 articles.

1. Comparison and predictors of rash associated with 15 antiepileptic drugs

2. Therapeutic Safety Monitoring: What to Look for and When to Look for It

3. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking

4. Predictors of Lamotrigine-associated Rash

5. Sunovion Pharmaceuticals Inc.APTIOM®(eslicarbazepine acetate) Prescribing Information.2015;http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022416s001lbl.pdf. Accessed June 22 2017.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thirteen years of experience with eslicarbazepine acetate in the United Kingdom and Republic of Ireland: A safety perspective;Epileptic Disorders;2023-08-26

2. DRESS with eslicarbazepine: The value of allergological exploration;Annales de Dermatologie et de Vénéréologie;2021-09

3. Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies;International Journal of Neuroscience;2021-06-01

4. Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention;Epilepsy & Behavior;2021-04

5. Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures;Epilepsy Research;2021-03